clinical trial · NCT05478525
A Study Evaluating the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
Glyscend, Inc.·phase2·completed·n = 51
Type 2 DiabetesGLY-200GLY-200GLY-200PlaceboPlaceboPlacebo
brief summary
This study is a Phase 2, randomized, double-blind, placebo-controlled, single-center study in adult patients with type 2 diabetes. It will evaluate the safety and tolerability of oral GLY-200. Subjects will participate in a ≤ 18-day screening period followed by a metformin washout period of approximately 14 days, and an inpatient period of 16 days. Approximately 48 subjects will be randomized to 1 of 3 active treatment groups or 1 of 3 placebo groups. Dosing will occur for 14 days. A follow-up clinic visit will occur on Day 21 \[End of Study (EOS)\] or Early Termination (ET).
started
Aug 3, 2022
primary completion
Mar 14, 2023
completion
Mar 14, 2023
last updated
Feb 10, 2025
official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol